Liquidia Stock Drops 50% After US Court Patent Ruling
Liquidia Corporation's shares fell nearly 50% on September 30 following a US federal court ruling against the company in its patent dispute with United Therapeutics. The decision raises concerns about the commercial prospects of Liquidia's key drug, Yutrepia, impacting investor confidence and the company's market position.
ET Markets·3h ago

